<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01326494</url>
  </required_header>
  <id_info>
    <org_study_id>H10-00184</org_study_id>
    <nct_id>NCT01326494</nct_id>
  </id_info>
  <brief_title>Reducing the Acute Care Burden of Childhood Asthma on Health Services in British Columbia</brief_title>
  <official_title>Reducing the Acute Care Burden of Childhood Asthma on Health Services in British Columbia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the benefits of giving filled prescription of a&#xD;
      medication to be used upon early onset of symptoms of URTI induced asthma. The hope is to&#xD;
      reduce the need to present to Health Care centres for treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In Canada, asthma affects more the 12% of children. Exacerbation are a common feature of&#xD;
      asthma. In children, upper respiratory tract infection (URTI's) are responsible for over 80%&#xD;
      of asthma exacerbation.&#xD;
&#xD;
      Experts in asthma care acknowledge this critical problem and have developed guidelines to&#xD;
      reduce asthma exacerbation.&#xD;
&#xD;
      The criteria for participation in this study to have 2 or more presentations to a Health&#xD;
      Service centre in the past 12 months for URTI induced asthma. These patients will be followed&#xD;
      and interviewed monthly over a 12 month period to investigate whether the use of Oral&#xD;
      cortico-steroids upon early onset of URTI induced asthma prevents the need for presentation&#xD;
      to hospital&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">May 2021</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of representation to Health Services for Exacerbation of URTI induced asthma</measure>
    <time_frame>One year</time_frame>
    <description>To review the effect of medication given at early onset of symptoms have on reducing the presentation to Health Services and Emergency Departments.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">92</enrollment>
  <condition>Upper Respiratory Tract Infection</condition>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Arm 1 Oral Cortico Steroid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A filled prescription will be given to be used upon early onset of symptoms.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual care for Asthma treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>monitor the readmission of URTI induced asthma in children over a 12 month period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arm 1 Oral Cortico Steroids</intervention_name>
    <description>Prednisolone: 1 mg / kg per day course of dose for 5 days up to child's weight of 20 kgs.&#xD;
Dexamethasone: 0.3mg/kg per dose for 3 days (minimum weight 20 kgs )</description>
    <arm_group_label>Arm 1 Oral Cortico Steroid</arm_group_label>
    <other_name>Prednisone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  2 or more presentations to Emergency department in a 12 month period&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  less then 2 presentations to Emergency department in a 12 month period&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruce Carleton, B.Pharm, Pharm.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of British Columbia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>BC Children's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H 3V4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 29, 2011</study_first_submitted>
  <study_first_submitted_qc>March 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2011</study_first_posted>
  <last_update_submitted>May 13, 2021</last_update_submitted>
  <last_update_submitted_qc>May 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of British Columbia</investigator_affiliation>
    <investigator_full_name>Bruce Carleton</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>Upper Respiratory Tract Infection</keyword>
  <keyword>Asthma</keyword>
  <keyword>URTI induced exacerbation of Asthma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Tract Infections</mesh_term>
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

